Clinical trials: Psychotic Symptoms
Severe Mental Illness, Depression / Major Depressive Disorder
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar…
- Conditions
- Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia
- Trial name
- LIFETRAIN (NCT07586150)
- Testing
- Semaglutide (SEMA), Exercise module, Anti-inflammatory diet module
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 140 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
HIV, STI
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
Despite advances in HIV/sexually transmitted infection (STI) prevention, Black youth account for the largest number of new HIV infections among heterosexual youth.
- Conditions
- HIV, STI, Emotional Disturbances, Mental Disorder
- Trial name
- NCT03348813
- Testing
- HIV/STI Prevention Intervention, General Health Control Intervention
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Perceptual Disorders, Confusion
Ketamine Challenge Study With JNJ-40411813
The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine.
- Conditions
- Perceptual Disorders, Confusion, Schizophrenia
- Trial name
- NCT01101659
- Testing
- JNJ-40411813, normal saline, ketamine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
- Trial name
- NCT07227818
- Testing
- NBI-1117568
- Where
- 25 sites in United States, Puerto Rico and 1 more
- Volunteers
- 560 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
PREvent First Episode Relapse (PREFER)
Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill.
- Trial name
- NCT00220714
- Testing
- atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- State University of New York - Downstate Medical Center
Psychotic Disorders, Hallucinations, Auditory
Testing a Peer-Support Group for Veterans Who Hear Voices
Veterans with schizophrenia spectrum disorders who experience psychosis struggle with social integration- e.g., participation in work, housing, and citizenship-due to symptoms, stigma, and psychosocial functioning deficits.
- Conditions
- Psychotic Disorders, Hallucinations, Auditory, Social Isolation
- Trial name
- VVV RCT (NCT07555275)
- Testing
- Veteran Voices and Visions (VVV), Wellness Recovery Action Planning (WRAP)
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Antipsychotic Drug
Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation
Antipsychotic medications are widely used to treat schizophrenia but may cause constipation, which can lead to abdominal discomfort, reduced quality of life, and poor treatment adherence.
- Trial name
- XQD-AIC (NCT07767526)
- Testing
- Xingqi Daozhi Decoction
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Psychological Trauma
Cognitive Behaviour Therapy for Voices and Dissociation
Case series design with participants with psychosis with a history of interpersonal trauma/abuse and current distressing auditory verbal hallucinations and dissociative experience.
- Conditions
- Schizophrenia, Psychological Trauma, Dissociation, Hallucinations
- Trial name
- NCT04990414
- Testing
- Cognitive Behavioural Therapy
- Volunteers
- 19 people
- Sponsor
- Greater Manchester Mental Health NHS Foundation Trust
Schizophrenia, Obesity
Multi-component Intervention for Diabetes in Adults With Serious Mental Illness
Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population.
- Conditions
- Schizophrenia, Obesity, Diabetes, Lifestyle Risk Reduction
- Trial name
- MIDAS (NCT03627377)
- Testing
- Multi-component Intervention for Diabetes in Adults with Serious Mental Illness
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- University of California, San Diego
Schizophrenia, Cognitive Dysfunction
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia
This study examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing inflammation in patients with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Dysfunction, Inflamation
- Trial name
- SUPPORT-SCZ (NCT07477301)
- Testing
- Structured Supportive Psychotherapy, Risperidone 2 mg
- Where
- Indonesia
- Volunteers
- 46 people
- Sponsor
- Hasanuddin University
Delusions, Schizophrenia
Metacognitive Training in Schizophrenia
Over a period of 4 weeks, metacognitive training for schizophrenia patients (MCT), delivered both in a group and individually, is compared to cognitive remediation (CogPack training).
- Trial name
- MCT (NCT01029067)
- Testing
- Metacognitive training, Cognitive Remediation
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Treatment-Resistant
An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms
The objectives of this study are to evaluate the safety and efficacy of Amisulpride as an add-on therapy or alternative monotherapy in treating patients with schizophrenia or schizoaffective disorder who have treatment-resistant…
- Trial name
- AmisulprideTRS (NCT05956600)
- Testing
- Amisulpride 50 MG
- Sponsor
- University of California, Los Angeles
Schizoaffective Disorder
Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia.
- Trial name
- SAPIN (NCT07058389)
- Testing
- 8-week outdoor physical activity program, 8-week indoor physical activity program
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Schizophrenia
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
- Trial name
- NCT01760993
- Testing
- SPD489
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Shire
Schizophrenia
The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
1. The title of this study is a multi-center,non randomized,open-labeled,intervention study:the efficacy and safety of intramuscular ziprasidone for three days in patients with acute psychotic agitation. 2.
- Trial name
- NCT02935998
- Testing
- Ziprasidone
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yang Fude
Schizophrenia, Negative Symptoms in Schizophrenia
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
- Trial name
- NCT06278532
- Testing
- Brief Negative Symptoms Scale, The Calgary Depression Scale for Schizophrenia, The Schizophrenia Cognition Rating Scale
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences
Schizophrenia
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
The project is designed to address the following two primary aims: 1. To determine whether adjunctive oxytocin is superior to placebo for the treatment of persistent negative symptoms, as measured by the SANS total score, in…
- Trial name
- CIDAR-3 (NCT01012167)
- Testing
- Oxytocin, Galantamine
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Maryland, Baltimore
Aphasia, Autism
Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain mental abilities.
- Conditions
- Aphasia, Autism, Schizophrenia
- Trial name
- NCT01602263
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.